New treatment using RNA interference for prostate cancer
Development of a novel, RNA-interference-based therapeutic to treat prostate cancer
This study is exploring a new treatment for prostate cancer that uses special molecules to target and shut down genes that help cancer cells survive, with the hope of offering a better option for patients battling this disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Nuago Therapeutics INC NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11004868 on NIH RePORTER |
What this research studies
This research focuses on developing a novel therapeutic approach for prostate cancer using RNA interference, which targets specific genes essential for cancer cell survival. The therapy utilizes short interfering RNA molecules derived from CAG trinucleotide repeat sequences, which have shown potential in reducing cancer cell viability. By downregulating the expression of genes associated with cancer, this treatment aims to provide a more effective option for patients suffering from prostate cancer. The research is based on findings from Northwestern University and aims to address the critical need for new prostate cancer therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with prostate cancer who are seeking new treatment options.
Not a fit: Patients with non-cancerous conditions or those who do not have prostate cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment option that significantly improves outcomes for prostate cancer patients.
How similar studies have performed: While RNA interference has been explored in various contexts, this specific application for prostate cancer represents a novel approach that has not been extensively tested.
Where this research is happening
Chicago, United States
- Nuago Therapeutics INC — Chicago, United States (Active)
Researchers
- Principal investigator: Schickel, Robert — Nuago Therapeutics INC
- Study coordinator: Schickel, Robert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.